NASDAQ:LXRX - US5288723027 - Common Stock
The current stock price of LXRX is 1.1 USD. In the past month the price increased by 2.8%. In the past year, price decreased by -36.42%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.87 | 371.68B | ||
AMGN | AMGEN INC | 13.19 | 154.89B | ||
GILD | GILEAD SCIENCES INC | 14.6 | 140.17B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.08 | 100.25B | ||
REGN | REGENERON PHARMACEUTICALS | 12.72 | 61.55B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
ARGX | ARGENX SE - ADR | 76.83 | 43.59B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.16 | 36.38B | ||
INSM | INSMED INC | N/A | 28.77B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.04B | ||
NTRA | NATERA INC | N/A | 23.09B | ||
BIIB | BIOGEN INC | 8.26 | 19.38B |
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 103 full-time employees. The company went IPO on 2000-04-07. The company is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The company has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. The company is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. The company is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.
LEXICON PHARMACEUTICALS INC
2445 Technology Forest Blvd, 11Th Floor
The Woodlands TEXAS 77381 US
CEO: Lonnel Coats
Employees: 103
Phone: 12818633000
The current stock price of LXRX is 1.1 USD. The price decreased by -4.35% in the last trading session.
The exchange symbol of LEXICON PHARMACEUTICALS INC is LXRX and it is listed on the Nasdaq exchange.
LXRX stock is listed on the Nasdaq exchange.
11 analysts have analysed LXRX and the average price target is 2.81 USD. This implies a price increase of 155% is expected in the next year compared to the current price of 1.1. Check the LEXICON PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
LEXICON PHARMACEUTICALS INC (LXRX) has a market capitalization of 399.74M USD. This makes LXRX a Small Cap stock.
LEXICON PHARMACEUTICALS INC (LXRX) currently has 103 employees.
LEXICON PHARMACEUTICALS INC (LXRX) has a support level at 1.07 and a resistance level at 1.19. Check the full technical report for a detailed analysis of LXRX support and resistance levels.
The Revenue of LEXICON PHARMACEUTICALS INC (LXRX) is expected to grow by 153.81% in the next year. Check the estimates tab for more information on the LXRX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
LXRX does not pay a dividend.
LEXICON PHARMACEUTICALS INC (LXRX) will report earnings on 2025-11-10, before the market open.
LEXICON PHARMACEUTICALS INC (LXRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.33).
The outstanding short interest for LEXICON PHARMACEUTICALS INC (LXRX) is 7.54% of its float. Check the ownership tab for more information on the LXRX short interest.
ChartMill assigns a technical rating of 7 / 10 to LXRX. When comparing the yearly performance of all stocks, LXRX is one of the better performing stocks in the market, outperforming 79.92% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to LXRX. LXRX has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months LXRX reported a non-GAAP Earnings per Share(EPS) of -0.33. The EPS increased by 57.69% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -53.47% | ||
ROE | -93.19% | ||
Debt/Equity | 0.43 |
11 analysts have analysed LXRX and the average price target is 2.81 USD. This implies a price increase of 155% is expected in the next year compared to the current price of 1.1.
For the next year, analysts expect an EPS growth of 62.83% and a revenue growth 153.81% for LXRX